Glenmark Life Sciences, a subsidiary of Glenmark Pharmaceuticals Ltd, is one of the leading developers and manufacturers of select high-value Active Pharmaceutical Ingredients. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
Financial Results:
- Glenmark Life Sciences Ltd reported Revenues for Q1FY24 of ₹578.00 Crores up from ₹490.00 Crore year on year, a rise of 17.96%.
- Total Expenses for Q1FY24 of ₹398.00 Crores up from ₹353.00 Crores year on year, a rise of 12.75%.
- Consolidated Net Profit of ₹135.00 Crores up 23.85% from ₹109.00 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹11.05, up 24.58% from ₹8.87 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.